"Cage vs Age": Development of an innovative nanotechnology to halt the spread of abnormal Tau protein in Alzheimer's Disease

Project Member(s): Care, A.

Funding or Partner Organisation: National Foundation for Medical Research and Innovation
National Foundation for Medical Research and Innovation

Start year: 2021

Summary: Current medications prescribed for Alzheimer's Disease (AD) alleviate the symptoms of the disease but do not alter the brain mechanisms underpinning it. Hence, a disease modifying treatment for AD remains a major unmet clinical need. Our first-of-its-kind approach, using a novel nanocage platform of our own design, represents a significant disruption in the AD therapeutic space, and is aimed at targeting and preventing the pathological spread of tau in the disease.

FOR Codes: Neurodegenerative Disorders Related to Ageing, Nanomedicine, Synthetic Biology, Neurosciences, Clinical health

Acknowledgement of Country

UTS acknowledges the Gadigal people of the Eora Nation, the Boorooberongal people of the Dharug Nation, the Bidiagal people and the Gamaygal people, upon whose ancestral lands our university stands. We would also like to pay respect to the Elders both past and present, acknowledging them as the traditional custodians of knowledge for these lands.